CLINICAL_TRIALS
trial_result
· 2021-02-26
Clinical Trial Update: Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout [Phase 2]
Summary
Phase 2 trial investigating febuxostat for lowering uric acid in patients with nonalcoholic fatty liver disease and gout.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ningbo No. 1 Hospital | Conditions: Nonalcoholic Fatty Liver Disease | Phase 2 | Status: UNKNOWN